Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging.

Nassif A, Jia J, Keiser M, Oswald S, Modess C, Nagel S, Weitschies W, Hosten N, Siegmund W, Kühn JP.

Radiology. 2012 Sep;264(3):741-50. doi: 10.1148/radiol.12112061. Epub 2012 Jul 6.

PMID:
22771883
2.

Polymorphisms in the organic anion transporting polypeptide genes influence liver parenchymal enhancement in gadoxetic acid-enhanced MRI.

Okubo H, Ando H, Kokubu S, Miyazaki A, Watanabe S, Fujimura A.

Pharmacogenomics. 2013 Oct;14(13):1573-82. doi: 10.2217/pgs.13.132.

PMID:
24088128
3.

Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.

Kindla J, Müller F, Mieth M, Fromm MF, König J.

Drug Metab Dispos. 2011 Jun;39(6):1047-53. doi: 10.1124/dmd.110.037622. Epub 2011 Mar 9.

4.

Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings.

Ziesenitz VC, König SK, Mahlke N, Jantos R, Skopp G, Weiss J, Haefeli WE, Mikus G.

Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):43-8. doi: 10.1111/bcpt.12066. Epub 2013 Apr 6.

5.

Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.

Oswald S, König J, Lütjohann D, Giessmann T, Kroemer HK, Rimmbach C, Rosskopf D, Fromm MF, Siegmund W.

Pharmacogenet Genomics. 2008 Jul;18(7):559-68. doi: 10.1097/FPC.0b013e3282fe9a2c.

PMID:
18551036
6.

Hepatic uptake of gadoxetic acid.

Kim H, Kim MJ.

Radiology. 2013 Apr;267(1):314-5. doi: 10.1148/radiol.13122292. No abstract available.

PMID:
23525720
7.

Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene.

Trdan Lušin T, Stieger B, Marc J, Mrhar A, Trontelj J, Zavratnik A, Ostanek B.

J Transl Med. 2012 Apr 25;10:76. doi: 10.1186/1479-5876-10-76.

8.
9.

SLCO1B1 polymorphism and oral antidiabetic drugs.

Kalliokoski A, Neuvonen PJ, Niemi M.

Basic Clin Pharmacol Toxicol. 2010 Oct;107(4):775-81. doi: 10.1111/j.1742-7843.2010.00581.x. Review.

10.

The double-edged sword of functional liver imaging.

Sahani DV, Agarwal S, Chung RT.

Radiology. 2012 Sep;264(3):621-3. doi: 10.1148/radiol.12121416. No abstract available.

PMID:
22919034
11.

Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.

Kunze A, Huwyler J, Camenisch G, Poller B.

Drug Metab Dispos. 2014 Sep;42(9):1514-21. doi: 10.1124/dmd.114.058412. Epub 2014 Jul 2.

12.

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.

Niemi M, Pasanen MK, Neuvonen PJ.

Pharmacol Rev. 2011 Mar;63(1):157-81. doi: 10.1124/pr.110.002857. Epub 2011 Jan 18. Review.

13.

Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation.

Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, Nakamoto A, Nagano H, Matsuura N, Wakasa K, Tomoda K.

Radiology. 2010 Jun;255(3):824-33. doi: 10.1148/radiol.10091557.

PMID:
20501720
14.

Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).

van de Steeg E, van der Kruijssen CM, Wagenaar E, Burggraaff JE, Mesman E, Kenworthy KE, Schinkel AH.

Drug Metab Dispos. 2009 Feb;37(2):277-81. doi: 10.1124/dmd.108.024315. Epub 2008 Nov 20.

15.

Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters.

Leonhardt M, Keiser M, Oswald S, Kühn J, Jia J, Grube M, Kroemer HK, Siegmund W, Weitschies W.

Drug Metab Dispos. 2010 Jul;38(7):1024-8. doi: 10.1124/dmd.110.032862. Epub 2010 Apr 20.

16.

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.

Hartkoorn RC, Kwan WS, Shallcross V, Chaikan A, Liptrott N, Egan D, Sora ES, James CE, Gibbons S, Bray PG, Back DJ, Khoo SH, Owen A.

Pharmacogenet Genomics. 2010 Feb;20(2):112-20. doi: 10.1097/FPC.0b013e328335b02d.

17.

Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.

Daka A, Dimovski A, Kapedanovska A, Vavlukis M, Eftimov A, Labachevski N, Jakjovski K, Geshkovska MN, Nebija D, Mladenovska K.

Pharmazie. 2015 Jul;70(7):480-8.

PMID:
26373210
18.

Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice.

van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH.

Clin Cancer Res. 2013 Feb 15;19(4):821-32. doi: 10.1158/1078-0432.CCR-12-2080. Epub 2012 Dec 14.

19.

Organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3: genetic variability and haplotype analysis in white Canadians.

Boivin AA, Cardinal H, Barama A, Pichette V, Hébert MJ, Roger M.

Drug Metab Pharmacokinet. 2010;25(5):508-15. Epub 2010 Sep 22.

20.

Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.

Lee HH, Leake BF, Teft W, Tirona RG, Kim RB, Ho RH.

Mol Cancer Ther. 2015 Apr;14(4):994-1003. doi: 10.1158/1535-7163.MCT-14-0547. Epub 2015 Feb 18.

Supplemental Content

Support Center